Condition: Classical Hodgkin Lymphoma · Sponsor: University of Cologne
The aim of the trial is to establish an individualized first-line treatment incorporating checkpoint inhibition for early-stage unfavorable cHL, which is effective and well tolerated.
This description comes directly from the study's public registry record.
Michael Fuchs · +49221478 · ghsg@uk-koeln.de
Always discuss trial participation with your own doctor first.
| 1st Department of Medicine, Cologne University Hospital | Cologne, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04837859